已收盘 04-02 16:00:00 美东时间
-0.060
-0.94%
今日重点评级关注:HC Wainwright & Co.:维持BridgeBio Oncology"买入"评级,目标价从27美元升至29美元;韦德布什:维持WAVE Life Sciences"跑赢大市"评级,目标价从33美元升至35美元
03-09 11:47
Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $8 to $9.
03-06 23:01
今日重点评级关注:HC Wainwright & Co.:维持NovoCure"买入"评级,目标价从47美元升至49美元;Citizens:维持Ironwood医药"跑赢大市"评级,目标价从8美元升至10美元
02-27 11:07
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Wednesday after volatile sessions ear
02-25 22:39
LifeStance Health Gr (NASDAQ:LFST) announced its Q4 earnings on Wednesday, Febr...
02-25 22:24
LifeStance Health Group shares are trading higher after the company reported be...
02-25 22:12
LifeStance Health Q4 revenue beats on higher visit volumes Overview Mental healthcare provider's Q4 revenue rose 17%, beating analyst expectations Adjusted EBITDA for Q4 beat analyst expectations Company announced $100 mln share repurchase program Outlook LifeStance expects 2026 revenue of $1.615 bl
02-25 19:14
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
2026 GuidanceLifeStance is providing the following outlook for 2026:The Company expects full year revenue of $1.615 billion to $1.655 billion, Center Margin of $526 million to $550 million, and Adjusted EBITDA of $185
02-25 19:06
2026 GuidanceLifeStance is providing the following outlook for 2026:The Company expects full year revenue of $1.615 billion to $1.655 billion, Center Margin of $526 million to $550 million, and Adjusted EBITDA of $185
02-25 19:05